The gene of an esterase enzyme, called paraoxonase (PON, EC.3.1.8.1.) is a member of a multigene family that comprises three related genes PON1, PON2, and PON3 with structural homology clustering on the chromosome 7.
Until now there were no data available about the PON2 codon 311 polymorphism in the normal Hungarian population (Table 1) . On the other hand significant inter-racial variability in the allelic distribution of other PON-like genes (PON1 and PON2) and risks associated with CHD were reported. [14] [15] [16] Since the Hungarian population is considered to be genetically and linguistically different from the other European ethnic groups and genetic differences have been reported in other lipid metabolism related genes such as the apoE polymorphism, 17, 18 it is also important to examine the inter-ethnic differences of other genetic risk factors such as the PON2 mutation. Our results indicate that the distribution of the PON2 genotype and allele fre- quencies is different in the normal Hungarian population from that in the Asian Indian, the only available examined group from the literature. 14 The Hungarians have less CC (8%) and more SS (53%) genotypes than the Asian Indians have, 17.5% and 40.2% respectively. In the Hungarian sample the PON*S allele was more frequent (73%) than in the Asian Indian group examined (61%). 14 The human genome contains three PON-like genes close to each other, but the function of these enzymes is still not clear. 2 Recently PON1 has emerged as an independent risk factor for cardiovascular disease. Despite the lack of its natural substrate there is growing evidence suggesting that as well as catalysing the hydrolysis of nerve toxic organophosphates, when PON1 is associated with high density lipoprotein (HDL), it may protect against LDL oxidation and prevent atherosclerosis formation by hydrolysing lipid peroxides, leukotriene-like compounds and therefore inhibiting the oxidation of HDL and low density lipoprotein (LDL). 19, 20 Furthermore, reduced PON1 activity has been found in patients with the risk of cardiovascular diseases such as hypercholesterolaemia, non-insulin-dependent diabetes, coronary heart disease and myocardial infarction. [3] [4] [5] On the other hand, not only PON1 activity, but also the polymorphism of the PON1 and PON2 genes has been found to be associated with the same cardiovascular risk factors and diseases. [6] [7] [8] Among the two common genomic variations of the PON1 gene, the codon 148 (Ala→Gly) mutation was reported to be associated with non-insulin-dependent diabetes 21 and might worsen glycaemia and lipidaemia in diabetic patients. The codon 192 mutation of the same gene was associated with the risk of coronary heart disease and had a synergistic effect with the codon 311 (Cys→Ser) polymorphism of another gene, the PON2 from the PON gene family.
14 It is pertinent to mention here that alterations of the serum PON activity have been described in AD recently, 22 but the PON1 gene polymorphism was not associated with either the severity of the atherosclerosis or the AD-like neuropathology in a different AD population. 23 Here we had similar results with the polymorphism of the PON2 gene and found that the frequencies of the PON2*S allele were 75% and 77% in the AD and VD groups, respectively, and no significant differences were found compared with controls (73%) ( Table 1) . Our results indicate that it is unlikely that the codon 311 (Cys→Ser) polymorphism of the PON2 gene alone has an impact on the development of AD and VD. Furthermore another cardiovascular disease and AD-related risk factor, the apoE polymorphism, was also determined in the present study. It was found that the apoE 3/4 genotype was more frequent, 28% and 25% in the AD and VD groups, than in the control group (12%) ( Table 1 ). The E4 allele was over-represented in both dementia groups (20% AD and 17% VD) compared with the controls (8%). One limitation of our study was that the dementia cases were only clinically diagnosed as AD and VD, and no autopsy data are available. Therefore we can not exclude the possibility that our VD group may include a substantial portion of mixed AD and VD cases. This potential diagnostic inaccuracy might explain the similarity of the E4 allele frequencies reported here in the AD and VD groups.
To investigate whether the PON2*S and apoE4 alleles are interactive regarding the dementia risk, the PON2 allele frequencies were calculated among the apoE4 allele carriers and non-carriers (Table 2) . Although the frequency of the PON2*S allele was comparable in both dementia cases and controls, it was significantly (P Ͻ 0.014) higher among the apoE4 allele carrier AD and VD cases (27% and 25% respectively) than in the corresponding controls (12%). The PON2*C allele was also more frequent among the AD (7%) and VD (6%) cases than in the control group (2%) but the difference was not significant (P Ͻ 0.106). Similar results with increased PON2*S allele frequency have been reported in association with CHD by others, 14 but no interactive effect was examined with the apoE4 allele. Our results indicate that atheroclerosis-related genetic risk factors might have importance in the development of the two most frequent dementing disorders, AD and VD. Therefore, besides the reported lipid metabolism-related risk factors such as the apoE polymorphism and the apo A-IV codon 360 mutation, 24 the PON2 codon 311 (Cys→Ser) mutation might have an interactive effect together with the apoE4 allele on the development of dementia.
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Methods
Case ascertainment and diagnosis
One hundred and fifty-nine Caucasian probands participated in our study. The 51 normal control persons (mean age ± SD, 71.8 ± 7 years; male/female 24/27; Mini-Mental State Exam (MMSE) score ± SD, 28 ± 1.3 points) were spouses of the AD and VD probands and none of them had verified symptoms of dementia. The 53 AD (mean age ± SD, 66.3 ± 10 years; male/female 17/36; MMSE score ± SD, 19 ± 2.2 points) and 55 VD (mean age ± SD, 72.9 ± 10.8 years; male/female 23/32; MMSE score ± SD, 22 ± 3.5 points) patients were selected from the outpatients of the local Memory Clinic. The clinical diagnosis of late onset sporadic AD was based on the DSM-III-R and NINCDS-ADRDA criteria. The AD probands were considered sporadic type, because none of them had a family history of dementia. The probable VD cases were diagnosed according to the criteria of ICD-10 and NINDS-AIREN for research studies. All patients underwent CT, MRI and SPECT studies in order to exclude any other neurological disorder. None of the probands had diabetes mellitus according to their blood sugar examination. Informed consent was obtained from each participant. The study was approved by the local Human Biomedical Research Ethics Committee.
Genetic analyses
Total genomic DNA was extracted from white blood cells using the method of Miller et al. 25 For the PON2 genotyping the DNA was amplified and the PCR reaction products were digested as proposed by Sanghera et al. 14 The forward primer 5Ј-ACA TGC ATG TAC GGT GGT CTT ATA-3Ј and the reverse primer 5Ј-AGC
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AAT TCA TAG ATT AAT TGT TA-3Ј were used to amplify the target region. The PCR-amplified product was detected by DdeI restriction enzyme followed by site fractionation on 8% polyacrylamide gel and visualization of bands with ethidium bromide. The apoE genotyping was performed as described earlier. 12 
Statistical analysis
Age and MMSE scores were normally distributed and compared by t-test. Alleles and genotypes were counted and their distribution between the groups was compared by 2 × 2 tables using Fisher's exact test. Pearson 2 test was used if less than five variables were counted within one subgroup. All significance tests were twotailed. The data were analyzed using SPSS for Windows (version 8.0)
